Efficacy and safety of tenecteplase versus urokinase in the treatment of acute ischemic stroke.

Medicine (Baltimore) · 2026 · PMC12991588 · PMID 41824817

Europe PMC DOI

hedged sentences

0.1070

closest p · 2.1× alpha

0.1290

boldest claim

The sentences

a nonsignificant trendP = .107not close (p > 0.1)

The onset-to-needle time showed a nonsignificant trend toward longer treatment delay in the Urokinase group (173.3 ± 39.9 vs 183.3 ± 38.2 minutes; t = −1.62, P = .107).

also in 5,406 other papers

did not reach statistical significanceP = .129not close (p > 0.1)

Any ICH within 24 to 36 hours was observed in 7 of 78 patients (9.0%) in the Tenecteplase group and 14 of 82 patients (17.1%) in the Urokinase group; this difference did not reach statistical significance (χ 2 = 2.300, P = .129).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.